Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02897297

Myeloproliferative Neoplastic Diseases Observatory From Brest

All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study.

Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis.

This is a not interventional study. Alive patients need to sign a non-opposition consent form.

Patients will be followed until last news (death, change of reference centre...).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Polycythemia Vera Blood Coagulation Disorders Blood Platelet Disorders Bone Marrow Diseases Bone Marrow Neoplasms Essential Thrombocythemia Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Hemorrhagic Disorders Myeloproliferative Disorders Neoplasms Neoplasms by Site Primary Myelofibrosis Thrombocythemia, Essential Thrombocytosis

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

Location status: Recruiting

Location contact

Eric Lippert, MD-PhD

CONTACT

Jean-Christophe Ianotto, MD

CONTACT

About this study

In this retrospective and prospective study, clinical and biological data from diagnosis until last news will be recorded.

Clinical data collected: patients and disease characteristics at the time of the diagnosis, disease and mutational status, cardio-vascular risk factors, history of thrombosis and cancer.

Biological data collected: hemogram and bone marrow results if available. During the follow-up new data will be noted: treatment changes (reasons of change and type of drug), thrombotic events (localization, date and hemogram), phenotypic evolutions (type and date), death (date and etiology).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis
  • Signature of the non-opposition consent form

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Overall Survival

    Time frame: 10 years

    occurrence of death

Secondary outcomes

  1. Incidence of evolutions

    Time frame: 10 years

    occurrence of transformation into polycythemia vera, secondary myelofibrosis, myelodysplastic syndrome or acute leukemia

  2. Incidence of thromboses

    Time frame: 10 years

    occurrence of arterial or venous thrombotic events

Study contacts

Contact information is provided by the study sponsor or research team.

Jean-Christophe Ianotto

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Observatoire Brestois Des Néoplasies Myéloprolifératives

Acronym: OBENE

Important dates

Study start
2015
Primary completion
2025
Study completion
2025
First posted
Sep 13, 2016
Registry last updated
Aug 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.